

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 12th June 2025

FOI Ref No 29165

Requested Information:

High-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

1) For the 4 months from January to April 2025, how many **unique*** patients received the following intra-vitreous treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab

*Please count a patient only once for any treatment, regardless of how many injections or implants they may have received

2) For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab – Lucentis
- Ranibizumab Biosimilar

Response:

- 1) For the 4 months from January to April 2025, how many **unique*** patients received the following intra-vitreous treatments for any eye condition:
 - Aflibercept **1279**
 - Bevacizumab **5**
 - Brolucizumab **0**
 - Dexamethasone **25**
 - Faricimab **1084**
 - Ranibizumab **123**

- 2) For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.
 - Aflibercept **63**
 - Bevacizumab **1**
 - Brolucizumab **0**
 - Dexamethasone **6**
 - Faricimab **127**
 - Ranibizumab – Lucentis **0**
 - Ranibizumab Biosimilar **0**

Attachment(s):

No Attachment(s)

Date Response sent: 19th June 2025